Related Experiment Video

Updated: May 15, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Factor VIII products and inhibitor development in severe hemophilia A

Samantha C Gouw1, Johanna G van der Bom, Rolf Ljung

  • 1Department of Pediatrics, Wilhelmina Children's Hospital, Utrecht, The Netherlands.

The New England Journal of Medicine
|January 18, 2013
PubMed

Insights

The type of factor VIII product used in previously untreated children with severe hemophilia A did not impact inhibitor development risk. However, second-generation recombinant products increased this risk compared to third-generation ones.

Area of Science:

  • Hematology
  • Pediatric Medicine
  • Immunology

Background:

  • Severe hemophilia A requires factor VIII (FVIII) replacement therapy.
  • Development of inhibitory antibodies (inhibitors) is a major complication in previously untreated patients.
  • The influence of FVIII product type and product switching on inhibitor development remains unclear.

Purpose of the Study:

  • To investigate the association between FVIII product characteristics and inhibitor development in previously untreated children with severe hemophilia A.
  • To compare the risk of inhibitor development with different types of FVIII products, including plasma-derived and recombinant formulations.
  • To assess the impact of switching FVIII products and von Willebrand factor content on inhibitor risk.

Main Methods:

  • A cohort of 574 previously untreated children with severe hemophilia A was evaluated.
  • Data on clotting-factor administration were collected for up to 75 exposure days.
  • Inhibitor development was defined by at least two positive inhibitor tests with decreased in vivo FVIII recovery.

Main Results:

  • The cumulative incidence of inhibitor development was 32.4% (177/574 children).
  • Plasma-derived and recombinant FVIII products showed similar risks of inhibitor development.
  • Second-generation full-length recombinant products were associated with a higher risk of inhibitor development compared to third-generation products (aHR, 1.60).
  • Von Willebrand factor content and switching products were not linked to inhibitor risk.

Conclusions:

  • FVIII product type (plasma-derived vs. recombinant) does not significantly alter inhibitor development risk.
  • Second-generation recombinant FVIII products pose a higher risk for inhibitor development than third-generation products.
  • Product switching and von Willebrand factor content are not associated with inhibitor development in this cohort.
Abstract

More Related Videos

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...